Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

NCT04185220 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

NIH

Sponsor class

Conditions

Adult T-Cell Lymphoma/Leukemia
Sezary Syndrome
Mycosis Fungoides

Interventions

DRUG: Recombinant human Interleukin-15 (rhIL-15)
BIOLOGICAL: Mogamulizumab

Sponsor

National Cancer Institute (NCI)